Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times

Gastroenterology

Volumn 141, Issue 2, 2011, Pages

  Memon, Khairuddin ^a   Kulik, Laura ^a   Lewandowski, Robert J ^a   Wang, Edward ^a   Riaz, Ahsun ^a   Ryu, Robert K ^a   Sato, Kent T ^a   Marshall, Karen ^a   Gupta, Ramona ^a   Nikolaidis, Paul ^a   Miller, Frank H ^a   Yaghmai, Vahid ^a   Senthilnathan, Seanthan ^a   Baker, Talia ^a   Gates, Vanessa L ^a   Abecassis, Michael ^a   Benson III, Al B ^a   Mulcahy, Mary F ^a   Omary, Reed A ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Embolization; Liver Cancer; Radiology; Treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; MITOMYCIN; SORAFENIB;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RADIOEMBOLIZATION; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 80051523274     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.04.054     Document Type: Article

References (41)

1. H.B. El-Serag Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 Suppl 1 2002 S74 S83
2. S.F.M.K. Alterkruse, and M.E. Reichman Hepatocellular carcinoma incidence, mortality, and survival benefits in the United States From 1975 to 2005 J Clin Oncol 27 2009 1485 1491
3. D.M.B.F. Parkin, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
4. F.X. Bosch, J. Ribes, and M. Diaz Primary liver cancer: worldwide incidence and trends Gastroenterology 127 Suppl 1 2004 S5 S16
5. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
6. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
7. R. Salem, R.J. Lewandowski, and L. Kulik Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 140 2011 497 507 e492
8. Y.K. Maddala, L. Stadheim, and J.C. Andrews Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization Liver Transpl 10 2004 449 455 (Pubitemid 38380323)
9. L.M. Kulik, B.I. Carr, and M.F. Mulcahy Safety and efficacy of (90)Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis Hepatology 47 2007 71 81
10. R. Salem, R.J. Lewandowski, and M.F. Mulcahy Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
11. R.J. Lewandowski, M.F. Mulcahy, and L.M. Kulik Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort Radiology 255 2010 955 965
12. R.J. Lewandowski, L.M. Kulik, and A. Riaz A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization Am J Transplant 9 2009 1920 1928
13. A. Riaz, F.H. Miller, and L.M. Kulik Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 2010 1062 1069
14. J.M. Llovet, M.I. Real, and X. Montana Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739 (Pubitemid 34607087)
15. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171 (Pubitemid 34454013)
16. R. Salem, R.J. Lewandowski, and B. Atassi Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival J Vasc Interv Radiol 16 2005 1627 1639 (Pubitemid 44431160)
17. A. Riaz, R.J. Lewandowski, and L. Kulik Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization Cardiovasc Intervent Radiol 33 2010 1143 1152
18. A. Riaz, L. Kulik, and R.J. Lewandowski Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres Hepatology 49 2009 1185 1193
19. A. Riaz, K. Memon, and F.H. Miller Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologicpathologic correlation J Hepatol 54 2011 695 704
20. M. Sala, J.M. Llovet, and R. Vilana Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma Hepatology 40 2004 1352 1360 (Pubitemid 39657009)
21. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
22. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables J Clin Oncol 26 2008 3913 3915
23. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442 (Pubitemid 36152543)
24. R. Salem, and K.G. Thurston Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations J Vasc Interv Radiol 17 2006 1251 1278 (Pubitemid 44259009)
25. R. Salem, R.J. Lewandowski, and V.L. Gates Research reporting standards for radioembolization of hepatic malignancies J Vasc Interv Radiol 22 2011 265 278
26. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430 (Pubitemid 32844200)
27. A. Forner, C. Ayuso, and M. Varela Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
28. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
29. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
30. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719 (Pubitemid 14202071)
31. J. Blade, A. Lopez-Guillermo, and F. Bosch Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients Br J Haematol 88 1994 117 121 (Pubitemid 24293862)
32. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
33. N. Mantel, and D. Byar Evaluation of response-time data invloving transient states: an illustration using heart-transplant data J Am Stat Assoc 69 1974 81 86
34. B. Gyorffy, A. Gyorffy, and Z. Tulassay The problem of multiple testing and solutions for genome-wide studies Orv Hetil 146 2005 559 563 (Pubitemid 46101028)
35. T.J. Cleophas, and A.H. Zwinderman Clinical trials are often false positive: a review of simple methods to control this problem Curr Clin Pharmacol 1 2006 1 4
36. V. Mazzaferro, E. Regalia, and R. Doci Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699 (Pubitemid 26079803)
37. D.J. Sargent, and D.F. Hayes Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol 26 2008 1922 1923
38. K. Okuda, T. Ohtsuki, and H. Obata Natural history of hepatocellular carcinoma and prognosis in relation to treatment Study of 850 patients Cancer 56 1985 918 928 (Pubitemid 15228292)
39. J.M. Llovet, J. Bustamante, and A. Castells Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 1999 62 67 (Pubitemid 29023987)
40. H. Gan, A. Grothey, and G. Pond Randomized phase II trials: inevitable or inadvisable? J Clin Oncol 15 2010 2641 2647
41. E. Green, G. Yothers, and D.J. Sargent Surrogate endpoint validation: statistical elegance versus clinical relevance Stat Methods Med Res 17 2008 477 486